• With considerable advances in therapy, including the introduction of ATRA initially as a single agent and then in combination with anthracyclines, and more recently by development of arsenic trioxide (ATO)-containing regimens, APL is now characterized by complete remission rates of 90% and cure rates of ∼ 80%, even higher among low-risk patients. (nature.com)
  • Half of the treated patients showed a complete (or near complete) remission of the disease. (wikipedia.org)
  • ONUREG is a nucleoside metabolic inhibitor indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy ( 1 ). (nih.gov)
  • In addition to the primary end point of OS, secondary end points include event-free survival, postinduction rates of complete remission (CR) and composite complete remission (CRc), and the percentage of patients who achieve CR or CRc with FLT3 -ITD measurable residual disease negativity. (onclive.com)
  • Took about 2 more weeks to have complete remission. (ulcertalk.com)
  • Secondary endpoints include event-free survival, post-induction rates of complete remission (CR) and composite complete remission (CRc), and the percentage of patients who achieve CR or CRc with FLT3 -ITD measurable residual disease negativity. (ntb.no)
  • NORTH CHICAGO, Ill. , Dec. 9, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive results from the Phase 3 induction study, U-ACHIEVE, which showed upadacitinib (45 mg, once daily) met the primary endpoint of clinical remission (per Adapted Mayo Score) at week 8, as well as all ranked secondary endpoints, in adult patients with moderate to severe ulcerative colitis. (abbvie.com)
  • Primary endpoint was clinical remission (per Adapted Mayo Score). (abbvie.com)
  • At week 8, patients (n=961) were evaluated for clinical remission, endoscopic healing, clinical response, change from baseline in the IBDQ score, and mucosal healing (an endpoint that includes both endoscopic healing and histologic healing). (jnj.com)
  • The primary endpoint is the proportion of patients in sustained remission until week 28 in the secukinumab group compared to the proportion of patients in the placebo group. (biomedcentral.com)
  • The study's primary endpoint will evaluate clinical remission measured after 10 weeks of SER-287 administration. (flagshippioneering.com)
  • The development of biologic anti-tumor necrosis factor (anti-TNF) agents (eg, infliximab, adalimumab, certolizumab pegol, and natalizumab) has significantly advanced the treatment of Crohn disease and improved the induction and maintenance of clinical remission in patients with moderate to severe disease, especially in those who are corticosteroid dependent. (medscape.com)
  • The new formulation was approved based on phase 3 pivotal trials that evaluated the safety and efficacy of infliximab-dyyb as maintenance therapy in patients with moderately to severely active UC (LIBERTY-UC) and CD (LIBERTY-CD). (medscape.com)
  • In both 54-week trials, infliximab-dyyb demonstrated superiority to placebo in the primary endpoints of clinical remission (UC and CD) and endoscopic response (CD) when given as maintenance therapy after induction therapy with IV infliximab. (medscape.com)
  • In the randomized, placebo-controlled, double-blind LIBERTY-UC study, 438 patients with moderately to severely active UC after induction therapy with IV infliximab were randomly assigned at week 10. (medscape.com)
  • This study was undertaken to evaluate the efficacy of infliximab (IFX) in treatment of Crohn's disease (CD) patients. (johnshopkins.edu)
  • Although some studies have compared the efficacy of infliximab (IFX) and cyclosporin A, there are no published studies comparing IFX and tacrolimus (Tac). (hindawi.com)
  • On the other hand, anti-TNF antibodies, such as infliximab (IFX) or adalimumab, and calcineurin inhibitors, such as cyclosporin A (CsA) or tacrolimus (Tac), have shown good salvage therapeutic efficacies for inducing remission in steroid-refractory UC. (hindawi.com)
  • The efficacy of infliximab is best documented although adalimumab and certolizumab pegol are moderately effective. (bmj.com)
  • At two months, my blood tests were great, and at six months, I entered clinical and endoscopic remission. (ulcertalk.com)
  • Data from a phase 3 trial published today in The New England Journal of Medicine show that upadacitinib-a breakthrough, once-daily oral medication-helps patients achieve and maintain clinical and endoscopic remission. (mountsinai.org)
  • Corresponding author Jean-Frederic Colombel, MD , notes, "Upadacitinib addresses an unmet need in the treatment of Crohn's disease and allows patients access to an oral medication that could put them in clinical and endoscopic remission. (mountsinai.org)
  • The primary efficacy endpoints were the proportion of patients with clinical remission at weeks 12 and 52 in ELEVATE UC 52 and week 12 in ELEVATE UC 12. (bvsalud.org)
  • Safety and pharmacokinetics, along with exploratory efficacy and biomarker endpoints including duration of CR were also evaluated. (ntb.no)
  • As early as week 4 in the induction studies, clinical response and clinical remission were achieved by significantly more subjects treated with SKYRIZI versus placebo, as were co-primary endpoints of endoscopic response and clinical remission at week 12 and week 52. (chemrobotics.in)
  • The patients treated with Skyrizi (600mg, IV) in the induction trials depicted a clinical remission of (43% & 35%) & an endoscopic response in (40% & 29%) @12wks vs (22% & 19%) & (12% & 11%) in PBO whereas those treated with Skyrizi (360mg, SC) in the maintenance trial depicted a clinical remission of 52% & an endoscopic response of 47% @52wks. (medphanut.com)
  • In the similarly designed LIBERTY-CD study, 343 patients with moderately to severely active CD after induction therapy were randomly assigned at week 10. (medscape.com)
  • The main purpose of this study is to evaluate the effect of efavaleukin alfa on induction of clinical remission in participants with moderately to severely active ulcerative colitis (UC). (policylab.us)
  • In these two phase 3 trials, we aimed to evaluate the safety and efficacy of etrasimod in adult patients with moderately to severely active ulcerative colitis. (bvsalud.org)
  • The aim of this study was to assess the efficacy and safety of adalimumab (ADA), a recombinant human monoclonal antibody against tumour necrosis factor α (TNF), for the induction of clinical remission in anti-TNF naïve patients with moderately to severely active ulcerative colitis. (digestivedashboard.nl)
  • ADA160/80 was safe and effective for induction of clinical remission in patients with moderately to severely active ulcerative colitis failing treatment with corticosteroids and/or immunosuppressants. (digestivedashboard.nl)
  • Third approved indication for SKYRIZI (risankizumab-rzaa) is supported by safety and efficacy data from two induction and one maintenance clinical trials evaluating SKYRIZI in moderately to severely active Crohn's disease, ADVANCE, MOTIVATE and FORTIFY. (chemrobotics.in)
  • A randomized, double-blind, multicenter phase III study to evaluate the long-term efficacy and safety of ABX464 25 mg or 50 mg once daily as a maintenance therapy in subjects with moderately to severely active ulcerative colitis. (who.int)
  • Pfizer announced detailed results from the first 2 pivotal Phase 3 trials of the OCTAVE program evaluating oral tofacitinib 10mg twice daily in inducing remission in adults with moderately to severely active ulcerative colitis (UC). (empr.com)
  • 53% women) received at least 2 courses of RTX to treat GPA relapses or to maintain remission. (elsevierpure.com)
  • However, 20-40% of patients fail to respond to corticosteroids (steroid-refractory UC) or fail to maintain remission without them (steroid-dependent UC) [ 1 - 5 ]. (hindawi.com)
  • Thiopurines such as azathioprine and 6-mercaptopurine are commonly used to maintain remission and are also suitable for reducing the dose of corticosteroids in patients with steroid-dependent UC. (hindawi.com)
  • CONCLUSIONS: This is the first pediatric, randomized, placebo-controlled trial that suggests the efficacy and safety of a highly concentrated mixture of probiotic bacterial strains (VSL#3) in active UC and demonstrates its role in maintenance of remission. (rejuvenation-science.com)
  • Ulcerative colitis long-term remission and maintenance with adalimumab 2 (ULTRA 2) was a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of adalimumab in induction and maintenance of clinical remission in 494 patients with moderate-to-severe ulcerative colitis who received concurrent treatment with oral corticosteroids or immunosuppressants. (digestivedashboard.nl)
  • A randomized placebo-controlled trial evaluated the efficacy of natalizumab induction therapy in patients with Crohn's disease. (qxmd.com)
  • The efficacy of filgotinib is being studied in a Phase IIb program (DARWIN trial 1, 2) with involvement of 886 rheumatoid arthritis patients and 180 Crohn's disease patients. (wikipedia.org)
  • Nevertheless, disease activity and drug clearance are higher at the induction phase leading to an increased risk of inadequate drug exposure and treatment failure. (ecco-ibd.eu)
  • Proactive TDM during induction phase, especially in naïve patients, could be a useful tool to obtain optimal IFX trough levels and to classify correctly primary failure. (ecco-ibd.eu)
  • QuANTUM-First is a randomized, double-blind, placebo-controlled, global phase 3 study evaluating quizartinib plus standard induction and consolidation therapy, including hematopoietic stem cell transplant (HSCT), and as maintenance monotherapy, in 539 adult patients aged 18 to 75 with newly diagnosed FLT3 -ITD positive AML. (onclive.com)
  • 1 U-ACHIEVE is the first of two Phase 3 induction studies to evaluate the safety and efficacy of upadacitinib in adults with moderate to severe ulcerative colitis. (abbvie.com)
  • Participants were randomly assigned to receive 45 mg of upadacitinib or placebo (2:1) for induction therapy to assess its effectiveness in achieving remission in two double-blind phase 3 trials, U-EXCEL and U-EXCEED. (mountsinai.org)
  • The maintenance phase evaluated the drug's ability to sustain remission and prevent relapse. (mountsinai.org)
  • Post hoc analyses were performed on pooled data from 2 replicate, phase 3, multicenter induction trials, U-ACHIEVE Induction and U-ACCOMPLISH, to determine the earliest time point of efficacy onset. (nih.gov)
  • Results from the induction phase of the Phase 3 UNIFI study show that treatment with a single IV dose of STELARA induced clinical remission in a significantly greater proportion of UC patients at week 8, compared with placebo, at both doses studied. (jnj.com)
  • Based on our consistent Phase 2a and Phase 2b data, we expect that the Phase 3 studies will support the short- and long-term efficacy and safety profile of obefazimod. (q4web.com)
  • The Phase 3 program will combine two induction trials and one single maintenance trial, involving a total of 1,200 patients and over 600 clinical study centers, mainly in North America, Europe, Latin America and Asia Pacific. (q4web.com)
  • Only phase 3, placebo-controlled or head-to-head randomized controlled trials assessing the efficacy of these medications as induction or maintenance therapies were included. (uchub360.com)
  • The FORTIFY study is a Phase 3, multicenter, randomized, double-blind, control group, 52-week maintenance study designed to evaluate the efficacy and safety of risankizumab 180 mg and 360 mg as maintenance therapy versus withdrawal in patients who responded to risankizumab induction treatment in the ADVANCE and MOTIVATE studies. (chemrobotics.in)
  • Three key phase-3 studies- FLAIR, ATLAS and ATLAS 2M- have evaluated the safety and efficacy of long-acting Cabotegravir/ Rilpivirine injection for treatment of HIV, with Orkin being the lead author of the FLAIR study. (theseoultimes.com)
  • This study is the maintenance phase of the Phase 3 clinical development program sequential to previous induction studies ABX464-105 and ABX464 106. (who.int)
  • Presentations are available online starting Friday, June 12, 2020, and include positive results from TOURMALINE-MM4, a Phase 3, randomized clinical trial evaluating the effect of single-agent oral NINLARO ™ (ixazomib) as a first-line maintenance therapy in adult patients diagnosed with multiple myeloma who had not been treated with stem cell transplantation. (takeda.com)
  • Pfizer announced top-line results from its first Phase 3 study, OPAL Broaden, evaluating the efficacy and safety of tofacitinib for the treatment of active psoriatic arthritis (PsA) in adults who had an inadequate response to at least one conventional synthetic disease-modifying antirheumatic drug (csDMARD) and who were tumor necrosis factor inhibitor (TNFi)-naïve. (empr.com)
  • Pfizer announced top-line results from two Phase 3 induction trials of tofacitinib for the treatment of adults with moderate to severe ulcerative colitis (UC). (empr.com)
  • In a phase I clinical trial, CD22 CAR T cells were able to induce remission in up to 80% of patients with CD19-negative ALL. (confex.com)
  • CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 3, 2019-- Seres Therapeutics, Inc . (Nasdaq:MCRB) today announced that it has enrolled the first patient in its Phase 2B trial, ECO-RESET, evaluating microbiome development candidate SER-287 in patients with active mild-to-moderate ulcerative colitis. (flagshippioneering.com)
  • A SER-287 Phase 1b placebo-controlled induction study in patients with mild-to-moderate active ulcerative colitis demonstrated a dose-dependent improvement of clinical remission rates and endoscopic scores and a favorable tolerability profile. (flagshippioneering.com)
  • SER-287 is currently being evaluated in a Phase 2B study in patients with active mild-to-moderate ulcerative colitis. (flagshippioneering.com)
  • MMF pharmacokinetics were studied in a multicenter Blood and Marrow Transplant Clinical Trials Network randomized phase II trial evaluating the effectiveness of MMF as one of 4 agents added to corticosteroids as treatment of aGVHD. (emmes.com)
  • Taken together, our studies demonstrated that IFX is efficacious and safe in inducing clinical remission, promoting mucosal healing, and downregulating Th1/Th17-mediated immune response in short course CD patients with luminal lesions. (johnshopkins.edu)
  • The induction trials showed mucosal healing & endoscopic remission in (21% & 14%) & (24% & 19%) of patients @12wks. (medphanut.com)
  • Upadacitinib demonstrated superior efficacy over placebo, with a statistically significant proportion of patients achieving clinical remission after induction therapy. (mountsinai.org)
  • Antibiotics can decrease anal fistula discharge and may induce remission in Crohn disease. (medscape.com)
  • CD19 directed CAR T cells have demonstrated the ability to induce complete remissions in up to 90% of r/r ALL patients. (confex.com)
  • Aims of our prospective, 1-year, placebo-controlled, double-blind study were to assess the efficacy of VSL#3 on induction and maintenance of remission and to evaluate the safety and tolerability of the probiotic preparation therapy in children with active UC. (rejuvenation-science.com)
  • To determine the tolerability of combination therapy with ruxolitinib and Early Intensification therapy in patients with activation of JAK-STAT signaling that can be inhibited by ruxolitinib and Day 15 or Day 22 MRD ≥5%, Day 42 MRD ≥1%, or LLy patients without complete response at the End of Induction and all patients with early T cell precursor leukemia. (centerwatch.com)
  • Patients who had a clinical response to upadacitinib induction therapy were then randomly assigned in the U-ENDURE maintenance trial to receive 15 mg or 30 mg of upadacitinib, or placebo (1:1:1) once daily for 52 weeks. (mountsinai.org)
  • We evaluated the efficacy of once-daily (QD) upadacitinib 45 mg, an oral, reversible Janus kinase inhibitor, on early symptomatic improvement for ulcerative colitis (UC). (nih.gov)
  • Although the use of upadacitinib was superior for the induction of clinical remission when compared with other agents commonly used to treat moderate-to-severe ulcerative colitis (UC), the biologic ranked highest in the incidence of adverse events (AEs), according to a new study. (uchub360.com)
  • Upadacitinib also ranked highest for the induction of clinical remission. (uchub360.com)
  • The authors concluded, "Upadacitinib was the best performing agent for the induction of clinical remission (the primary outcome) but the worst performing agent with regard to adverse events in patients with moderate-to-severe ulcerative colitis. (uchub360.com)
  • As someone dedicated to improving the lives of patients with IBD, I am excited to see data supporting the efficacy and safety of a new formulation offering convenience and improved access to a well-known and proven drug," Andres Yarur, MD, of Cedars-Sinai Medical Center, Los Angeles, California, said in a news release . (medscape.com)
  • You may be eligible to participate in a research opportunity evaluating the safety and effectiveness of an investigational study drug. (policylab.us)
  • Objectives To evaluate the efficacy and safety of dietary interventions on IBD outcomes. (johnshopkins.edu)
  • Safety, pharmacokinetics, and other efficacy and biomarker end points including duration of CR were also evaluated. (onclive.com)
  • Objective This study was conducted to evaluate the efficacy and safety of repeated and prolonged B cell depletion with rituximab (RTX) for the maintenance of long-term remission in patients with chronic relapsing granulomatosis with polyangiitis (Wegener's) (GPA). (elsevierpure.com)
  • The significant rates of remission observed through the 8-week induction, coupled with a safety profile that is well-documented through years of research and use in other immune diseases, demonstrate the potential for ustekinumab as an effective treatment for UC. (jnj.com)
  • It is designed to evaluate efficacy and safety of secukinumab compared to placebo in combination with an open-label prednisolone taper regimen. (biomedcentral.com)
  • The trial design allows the first placebo-controlled data collection on the efficacy and safety of secukinumab in patients with GCA. (biomedcentral.com)
  • Lasa JS, Olivera PA, Danese S, Peyrin-Biroulet L. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. (uchub360.com)
  • Takeda is also presenting key insights from the US MM-6 trial, which investigates the effectiveness and safety of an in- class transition to oral NINLARO in combination with lenalidomide and dexamethasone in newly diagnosed multiple myeloma patients who have previously received a parenteral bortezomib-based triplet induction therapy. (takeda.com)
  • The first evaluates the tacrolimus + azathioprine + corticosteroid (TAC) scheme compared with cyclosporine + azathioprine + corticosteroid (CAC), in which the incremental cost-effectiveness ratio indicates that 1 additional rejection avoided has a cost of US dollar $5461.09 which, compared with the cost-effectiveness threshold in the base case, indicates that the TAC scheme is not a cost-effective (CE) strategy with respect to the CAC scheme. (bvsalud.org)
  • In remission group, significant changes were observed in CDAI, the Simple Endoscopic Score for Crohn's Disease (SES-CD), and serum indexes. (johnshopkins.edu)
  • Response and remission rates for natalizumab were superior to those for placebo at Weeks 4, 8, and 12, demonstrating the early and sustained efficacy of natalizumab as induction therapy in patients with elevated C-reactive protein and active Crohn's disease. (qxmd.com)
  • Adalimumab was safe and more effective than placebo in inducing and maintaining clinical remission in patients with moderate-to-severe ulcerative colitis who did not have an adequate response to conventional therapy with steroids or immunosuppressants. (digestivedashboard.nl)
  • Results of this Long-Term Extension (LTE) of the SELECT-COMPARE study show that RINVOQ plus MTX maintained higher levels of clinical response, including remission compared to adalimumab plus MTX, through week 72. (pharmiweb.com)
  • Patients achieving remission, who did not undergo a consolidative hematopoietic stem cell transplant, were found to be at high risk of relapse due to downregulation of the CD22 antigen below the threshold required for effective CD22 CAR T cell activity. (confex.com)
  • Antitumor necrosis factor antibodies and calcineurin inhibitors have shown good therapeutic efficacy for steroid-refractory ulcerative colitis (UC). (hindawi.com)
  • PHILADELPHIA, PENNSYLVANIA, October 9, 2018 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data showing treatment with a single intravenous (IV) dose of STELARA ® (ustekinumab) induces clinical remission and response in adults with moderate to severe ulcerative colitis (UC) who previously experienced an inadequate response or were intolerant to conventional or biologic therapies. (jnj.com)
  • Ulcerative colitis is a complex immune disease, and more than half of UC patients have not experienced remission with currently available conventional or biologic treatment options," said lead investigator Bruce E. Sands, MD, Dr. Burrill B. Crohn Professor of Medicine and Chief of the Dr. Henry D. Janowitz Division of Gastroenterology at the Icahn School of Medicine at Mount Sinai. (jnj.com)
  • Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. (rejuvenation-science.com)
  • Its efficacy as maintenance therapy for patients with ulcerative colitis has not been studied in a controlled, double-blind trial. (digestivedashboard.nl)
  • [ 84 ] Anti-TNF agents are effective for induction and maintenance of remission in patients with Crohn disease and active inflammation. (medscape.com)
  • Anti-TNF antibodies are usually administered for both inducing and maintaining remission consecutively. (hindawi.com)
  • To understand the difference in efficacy between treatment with anti-TNF antibodies and calcineurin inhibitors, some studies have compared the therapeutic outcomes with IFX-based treatment versus CsA-based treatment [ 17 - 20 ]. (hindawi.com)
  • Clinical and biochemical responses to treatment should be determined in the 12-week period after the initiation of therapy, and endoscopy or transmural responses to therapy should be evaluated in the 6 months after the start of therapy. (medscape.com)
  • The aim of the study was to evaluate the efficacy of the implementation of an early proactive TDM strategy, comparing clinical remission (CR) and biochemical remission (BR) at week 14 and 52, and endoscopic improvement (EI) between two groups. (ecco-ibd.eu)
  • Participants will be randomized to receive 1 of 3 efavaleukin alfa doses or placebo during a 12-week induction period. (policylab.us)
  • Participants who complete the 12-week induction period will have the option to enter an exploratory long-term treatment period for up to 40 weeks (total of up to 52 weeks of treatment) if, in. (policylab.us)
  • U-EXCEED had an additional 12-week open-label, active single-group induction period to allow for the accrual of enough patients for entry into U-ENDURE. (mountsinai.org)
  • ELEVATE UC 52 comprised a 12-week induction period followed by a 40-week maintenance period with a treat-through design. (bvsalud.org)
  • ELEVATE UC 12 independently assessed induction at week 12. (bvsalud.org)
  • Regression analysis determined the association between changes in UC symptoms and the likelihood of achieving clinical remission/response per Adapted Mayo score at week 8. (nih.gov)
  • Early improvement in stool frequency and bowel urgency by day 3 and reductions in hs-CRP and FCP by week 2 were significantly associated with clinical remission/response at week 8. (nih.gov)
  • Corticosteroid-free remission(SFR) was assessed at week 14 and 30. (ecco-ibd.eu)
  • Serum immune proteins which demonstrated a significant week 0 to 6 change were evaluated as candidate biomarkers of week 14 and 30 SFR. (ecco-ibd.eu)
  • Subsequently, at the request of European regulatory authorities, the protocol was amended to include a second induction group (ADA80/40: 80 mg at week 0, 40 mg at weeks 2, 4 and 6). (digestivedashboard.nl)
  • At week 8, 18.5% of patients in the ADA160/80 group (p = 0.031 vs placebo) and 10.0% in the ADA80/40 group (p = 0.833 vs placebo) were in remission, compared with 9.2% in the placebo group. (digestivedashboard.nl)
  • Patients who do not achieve remission by week 12 experience a flare after remission or cannot adhere to the prednisolone tapering will enter the escape arm and receive prednisolone at a dose determined by the investigator's clinical judgment. (biomedcentral.com)
  • Natalizumab induced response and remission at Week 8 that was sustained through Week 12. (qxmd.com)
  • Ten weeks after therapy, 61 (57.5%) patients achieved clinical remission, 17 (16.0%) had clinical response, and the remaining 28 (26.4%) were failed. (johnshopkins.edu)
  • IFX markedly downregulated Th1/Th17-mediated immune response but promoted IL-25 production in intestinal mucosa from remission group. (johnshopkins.edu)
  • There was no significant difference in the colectomy-free rate, clinical remission rate, and clinical response rate at 2 months between the groups. (hindawi.com)
  • Inclusion criteria: 1.Subjects must have completed the induction treatment study (ABX464-105 or ABX464 106), and subjects' clinical response status must be available. (who.int)
  • All eligible subjects who have completed either one of the induction studies above mentioned, will be encouraged to take part in the present ABX464-107 maintenance study and will be randomized to either a double blind, placebo-controlled part (Part #1) or allocated to ABX464 50mg or 25mg blinded ABX464 treatment arms (Part #2) depending on their clinical response at the end of induction as shown below. (who.int)
  • 150 points) and response or remission over time. (qxmd.com)
  • After induction and consolidation therapy, the overall response rate was 86%, with 69% complete remissions (CR). (angelaserra.com)
  • medical citation needed] They show long-term efficacy in the treatment of various inflammatory diseases. (wikipedia.org)
  • The follow up dose for adult patients with GPA and MPA who have achieved disease control with induction treatment, in combination with glucocorticoids is two 500 mg intravenous infusions separated by two weeks, followed by a 500 mg intravenous infusion every 6 months thereafter based on clinical evaluation ( 2.6 ). (drugs.com)
  • OBJECTIVES: To evaluate the cost-effectiveness of pharmacological treatment in maintenance therapy for adult heart transplant recipients from the Colombian health system perspective. (bvsalud.org)
  • Patients were randomly assigned 1:1 to receive quizartinib or placebo plus cytarabine and anthracycline induction and cytarabine consolidation chemotherapy followed by up to 3 years of treatment with quizartinib or placebo, respectively. (onclive.com)
  • Existing treatment options often fall short in achieving sustained remission and controlling symptoms. (mountsinai.org)
  • Owing to the excellent efficacy of systemic administration of corticosteroids, most patients achieve remission even if they required second-line treatment. (hindawi.com)
  • Other drugs such as thiopurines are used for maintaining remission when the remission was achieved with calcineurin inhibitors because of the absence of long-term treatment data. (hindawi.com)
  • Moreover, there are no published data with which to compare therapeutic efficacies between IFX-based treatment and Tac-based treatment. (hindawi.com)
  • n=14) or an identical placebo (n=15) in conjunction with concomitant steroid induction and mesalamine maintenance treatment. (rejuvenation-science.com)
  • ATLAS 2M study evaluated if the treatment duration could be increased to once every two months and was done on people who were already on monthly Cabotegravir/ Rilpivirine. (theseoultimes.com)
  • Exclusion criteria: 1.Subjects who permanently discontinued the study treatment during the induction study (either ABX464-105 or ABX464-106). (who.int)
  • Seres is advancing SER-401 to augment the efficacy of immuno-oncology treatment. (flagshippioneering.com)
  • Two toxic deaths (0.8%) occurred during induction treatment. (angelaserra.com)
  • Several subsequent hypnosis studies by the same Manchester group [10-13] and by other investigators in IBS severity was scored before and after many countries [14-17] have confirmed the treatment using the Irritable Bowel Severity high efficacy of hypnosis in IBS treatment. (who.int)
  • Vedolizumab(VDZ) is a monoclonal antibody targeting α4β7-integrin which has demonstrated efficacy as induction and maintenance therapy for inflammatory bowel disease(IBD). (ecco-ibd.eu)
  • Changes in serum immune protein concentrations with pro-inflammatory, immunoregulatory and chemotactic functions are observed following VDZ induction therapy. (ecco-ibd.eu)
  • RESULTS: All 29 patients responded to the inflammatory bowel disease (IBD) induction therapy. (rejuvenation-science.com)
  • 001). Sustained remission occurred in 26% of natalizumab-treated patients and 16% of patients receiving placebo (P = .002). (qxmd.com)
  • In 1973, daunorubicin (DNR) was shown to increase remission rates from 13 to 58% and to reduce hemorrhage-related mortality after 5 days of therapy relative to 6-MP-based regimens. (nature.com)
  • We aimed to characterise changes in serum immune protein profiles following VDZ induction therapy and evaluate the association between serum immune protein profiles and outcome of VDZ therapy. (ecco-ibd.eu)
  • IBD patients commencing VDZ induction therapy were prospectively recruited. (ecco-ibd.eu)
  • All patients received glucocorticoids and mesalazine until remission occurred, and then continued to receive mesalazine as maintenance therapy. (rejuvenation-science.com)
  • Daiichi Sankyo (TSE: 4568) announced that quizartinib has been recommended for approval in the European Union (EU) in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by quizartinib single-agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 -ITD positive. (ntb.no)
  • Of these, 23 studies evaluated induction therapy with either a biologic or small molecule drug, comprising 10,061 patients with UC. (uchub360.com)
  • To use data from clinical genomic sequencing of diagnosis, germline/remission and MRD samples to guide therapy, including incorporation of targeted agents and institution of genetic counseling and cancer surveillance. (centerwatch.com)
  • Despite this remarkable upfront success, relapse after CAR T cell therapy remains a major obstacle to long term remissions. (confex.com)
  • Higher doses may improve the efficacy of MMF as aGVHD therapy. (emmes.com)
  • This study aimed to compare therapeutic efficacies between IFX- and Tac-based strategies for steroid-refractory UC. (hindawi.com)
  • The findings of our study showed that IFX and Tac have similar short-term therapeutic efficacy for steroid-refractory UC. (hindawi.com)
  • a Clinical remission per Adapted Mayo Score is defined as stool frequency subscore (SFS) ≤1 and not greater than baseline, rectal bleeding subscore (RBS) of 0 and endoscopic subscore ≤1. (abbvie.com)
  • Purpose To evaluate the efficacy of rituximab maintenance in 60- to 75-year-old patients with advanced follicular lymphoma responding to brief first-line chemoimmunotherapy followed by rituximab consolidation. (angelaserra.com)
  • Conclusion A brief R-FND induction plus rituximab consolidation achieved excellent results with high CR and PFS rates, supporting the feasibility of this regimen in patients older than 60 years. (angelaserra.com)
  • The use of RTX for the maintenance of long-term remission merits further formal investigation. (elsevierpure.com)
  • Children were prospectively evaluated at four time points: within 1 month, 2 months, 6 months, and 1 year after diagnosis or at the time of relapse. (rejuvenation-science.com)
  • Uncontrolled pilot studies suggest that a probiotic preparation (VSL#3) maintains remission in mild to moderate UC and reduces active inflammation in adult patients. (rejuvenation-science.com)
  • The low FODMAP diet has shown benefit for functional symptoms in IBD, yet efficacy regarding inflammation is lacking. (springer.com)
  • The induction dose for adult patients with active GPA and MPA in combination with glucocorticoids is 375 mg/m 2 once weekly for 4 weeks. (drugs.com)
  • 0.001) and correlating with the increased in vivo efficacy of the CAR T cells against CD22 WT NALM6, relative to CD22 Lo NALM6. (confex.com)
  • The objective of this study was to evaluate the influence of chamomile tea associated with a rigorous oral hygiene in the OM prevention. (bvsalud.org)
  • No differences between active interventions were detected when evaluating AEs and serious AEs. (uchub360.com)
  • To evaluate and implement deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) sequencing-based methods to monitor levels of MRD in bone marrow, blood, and cerebrospinal fluid. (centerwatch.com)
  • Thus, strategies to increase the antigen-sensitivity of CD22 CAR T cells have the potential to enhance the induction and duration of remission in ALL patients. (confex.com)